bearish
Biosimilar Battlefield: U.S. Humira Pushed to 2023
519 Views04 Oct 2017 00:25
We are updating our market model to reflect the patent litigation settlement between Amgen Inc (AMGN US) and Abbvie Inc (ABBV US) , the...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
- The Two Weeks in NorthAsia@Smartkarma That Were: BOJ/N225, Buybacks, & Biosimilars26 Feb 2018
- Biosimilar Battlefield: An Update15 Feb 2018
- Wuxi Biologics Placement - Selldown Right when Lockup Expires Suggests Eagerness to Offload13 Dec 2017
- Biosimilar Battlefield: U.S. Humira Pushed to 202304 Oct 2017
- Biosimilar Battlefield: Celltrion Forecasts24 Sep 2017
- Biosimilar Battlefield: Samsung Bioepis Forecast13 Sep 2017
- Surveying The Biosimilar Battlefield08 Sep 2017
x